Bleeding risk with the new oral anticoagulant drugs (NOACs) is increased when they are used with some other medications, including amiodarone, often co-prescribed with these agents, a new study warns.

A common scenario: a patient presents with new-onset atrial fibrillation (AF) and multiple risk factors for stroke. Everyone agrees to use anticoagulant therapy to reduce the risk of stroke. The ...

HOUSTON, TX—There’s no such thing as a good intracranial hemorrhage (ICH), but a new analysis hints that patients who have one might be better off if they’re taking a non-vitamin K antagonist oral ...

Patients with nonvalvular atrial fibrillation treated with non-vitamin K oral anticoagulants (NOACs) have a heightened risk of major bleeding when also treated with other medications, including ...

BOSTON -- Lower adherence to non-vitamin K antagonist oral anticoagulant (NOACs) might wipe out the advantage over warfarin (Coumadin), according to a large real-world observational study. In an ...

Stroke patients treated with intravenous alteplase (Activase) did not have more intracranial hemorrhages if they had recently taken non-vitamin K antagonist oral anticoagulants (NOACs), according to ...

(HealthDay News) — Non-vitamin K antagonist oral anticoagulants (NOACs) have been adopted into practice and are more frequently prescribed than vitamin K antagonists (VKAs) in the Global Registry on ...

Amag Pharma has struck a merger deal with Perosphere, adding an anticoagulant reversal agent in midstage trials to its emerging hematology business. The terms of the deal see Amag making an upfront ...